Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Dermatologic 3Sarcoma 1

Conditions

Melanoma 864Lymphoma, T-Cell, Cutaneous 143Uveal Melanoma 96Skin Neoplasms 96Mycosis Fungoides 95Sezary Syndrome 81Carcinoma, Basal Cell 76Neoplasm Metastasis 68Lymphoma 64Lymphoma, Non-Hodgkin 63Keratosis, Actinic 61Neoplasms 57Leukemia, Lymphocytic, Chronic, B-Cell 57Carcinoma, Renal Cell 55Carcinoma, Non-Small-Cell Lung 54Lymphoma, B-Cell, Marginal Zone 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 52Lymphoma, Follicular 52Hodgkin Disease 52Lymphoma, Large-Cell, Immunoblastic 50Carcinoma, Merkel Cell 50Burkitt Lymphoma 49Brain Neoplasms 46Multiple Myeloma 44Lymphoma, Large-Cell, Anaplastic 41Recurrence 40Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40Breast Neoplasms 40

Interventions

Brentuximab Vedotin 3Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphomatoid Papulosis × Dermatologic × Clear all
NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
79 enrolled
DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
26 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT00099255 2014-12-18

Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma

Seagen Inc.

Phase 2 Completed
40 enrolled
DermatologicLymphoidSarcoma

Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡